Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC
Posted: Friday, March 19, 2021
According to Caicun Zhou, PhD, MD, of the Shanghai Pulmonary Hospital, China, and colleagues, the bispecific PD-L1 and CTLA-4 antibody KN046 appeared to be safe and active as a second-line treatment in patients with metastatic non–small cell lung cancer (NSCLC). The results of this phase II study were presented in January 2021 during the virtual edition of the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore (WCLC; Abstract P77.03).
Patients were administered 3 mg/kg (cohort A: n = 30) or 5 mg/kg (cohort B: n = 33) of KN046 once every 2 weeks. Adverse events of grade 3 or higher and severe adverse events were reported in 33.3% and 25.4% of patients, respectively. Immune-related adverse events occurred in 54.0% of patients; of them, 17.5% experienced toxicity of grade 3 or higher. Infusion-related reaction (25.4%), anemia (22.2%), rash (20.6%), hyperglycemia (19.0%), abnormal hepatic function (15.9%), hypothyroidism (15.9%), alanine aminotransferase increase (12.7%), asthenia (12.7%), aspartate aminotransferase increase (11.1%), and pruritus (11.1%) were among the most frequently reported treatment-related adverse events. Both cohorts exhibited similar safety profiles.
At the cutoff date, 37.5% of patients remained on treatment. The objective response rate was 10.7% in cohort A and 15.6% in cohort B. The disease control rate was higher in cohort A than in cohort B (82.1% vs. 62.5%). The median duration of progression-free survival was 3.7 months. At 3, 6, and 9 months, the progression-free survival rates were 64.1%, 36.6%, and 34.2%, respectively; the overall survival rates were 91.4%, 86.9%, and 81.0%, respectively. In patients with squamous disease, the median duration of progression-free survival was 7.3 months. In this population, the progression-free survival rates were 80.0%, 55.9%, and 46.6% at 3, 6, and 9 months, respectively; the overall survival rates were 100.0%, 88.2%, and 88.2%, respectively.
Disclosure: For full disclosures of the study authors, visit wclc2020.iaslc.org.
